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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological
agent of Kaposi’s sarcoma, primary effusion lymphoma (PEL), and
multicentric Castleman’s disease. Like other herpesviruses, KSHV
establishes life-long latency in the human host with intermittent
periods of reactivation. Physiological triggers of herpesviral reactiva-
tion are poorly defined. Toll-like receptors (TLRs) recognize pathogens
and are vital for the host innate immune response. We screened
multiple TLR agonists for their ability to initiate KSHV replication in
latently infected PEL. Agonists specific for TLR7/8 reactivated latent
KSHV and induced viral lytic gene transcription and replication.
Furthermore, vesicular stomatitis virus (VSV), a bonafide physiolog-
ical activator of TLR7/8, also reactivated KSHV from latency. This
demonstrates that secondary pathogen infection of latently infected
cells can reactivate KSHV. Human herpesviruses establish life-long
latency in the host, and it is plausible that a latently infected cell will
encounter multiple pathogens during its lifetime and that these
encounters lead to episodic reactivation. Our findings have broad
implications for physiological triggers of latent viral infections, such
as herpesviral reactivation and persistence in the host.
TLR7  TLR8
Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) is amember of the gammaherpesviridae. KSHV is the etiolog-
ical agent of Kaposi’s sarcoma (KS), the most common AIDS-
associated malignancy, and is causally linked to two B cell
lymphoproliferative disorders, primary effusion lymphoma
(PEL) and multicentric Castleman’s disease (MCD) (1, 2). All
herpesviruses, including KSHV, exhibit both latent and lytic
phases during their lifecycle. B lymphocytes are the primary
latent reservoir of KSHV, although KSHV can persist latently in
multiple cell types (3). KSHV reactivates and replicates in
response to chemical compounds such as 12-O-tetradecanoyl-
phorbol-13-acetate (TPA/PMA) or butyrate. Demethylation of
the promoter for the KSHV replication and transcription acti-
vator (RTA), and activation of the protein kinase C pathways
occur in response to treatment with these agents.
Toll-like receptors (TLRs) mediate innate immunity and recog-
nize molecular patterns unique to pathogens, for example, bacteria,
fungi, or viruses (4). Several TLRs reside within endosomes and can
recognize either RNA (TLRs 3, 7, and 8) or DNA (TLR9) (4). The
TLR pathway can also be activated by endogenous host stimuli,
such as components of dying cells. Thus, cellular RNA released
from apoptotic or necrotic cells can activate TLR7 and TLR8 as
well (5). PEL are considered post-germinal center B cells (2).
Normal germinal center B cells express TLR1, as well as TLR6
through TLR10 (6). Therefore, endosomal TLRs constitute the
majority of TLRs expressed in B cells, and the TLRs expressed in
PEL were hitherto unknown.
TLR activation stimulates the transcription of IFN regulatory
factors (IRF) and NF-B transcription factors. We have previously
reported that KSHV infection of monocytes leads to the up-
regulation of TLR3 and its downstream targets, IFN-1 and
CXCL10 (7). Moreover, TLR4 has been shown to mediate innate
immune responses against KSHV in endothelial cells (8).
A central question regarding the KSHV viral lifecycle relates to
the physiological trigger that governs the switch from viral latency
to lytic replication. We hypothesized that during its lifetime, a
KSHV latently infected B cell would encounter additional second-
ary pathogens or other stimuli, for example, nucleic acids released
from necrotic cells, which would trigger TLR signaling in latently
infected cells. We speculated that these would be physiological
triggers for viral reactivation of KSHV from latency.
To test this hypothesis, we screened several latently infected PEL
cell lines with agonists specific for different human TLRs. Stimu-
lation of KSHV infected latent B lymphocytes with the TLR8
ligand, single-stranded polyuridine (ssPoly-U), a synthetic ssRNA
homolog, strongly reactivated KSHV from latency. Stimulation
with synthetic TLR7 ligands also reactivated the virus, albeit to a
lesser extent than ssPoly-U. To test the hypothesis that TLR7/8
activation resulted in authentic viral reactivation, we analyzed
KSHV transcription in four different PEL cell lines that were
stimulated with TLR7/8 ligands. In all cases, TLR7/8 activation
triggered the signature lytic reactivation pattern of transcription. In
contrast, stimulation with LPS, a ligand for TLR4, did not reactivate
KSHV from latently infected B lymphocytes and did not induce
significant changes in viral transcription. Additionally, we deter-
mined whether a physiological trigger of TLR7/8 could also reac-
tivate KSHV. We infected PEL with a secondary pathogen, VSV,
a known inducer of TLR7/8 signaling, and found that VSV infection
also induced KSHV reactivation from latency. Thus, our findings
demonstrate a link between innate immune activation and viral
reactivation from latency and suggest that single-stranded RNA can
serve as a biological trigger for KSHV reactivation from B lym-
phocytes.
Results
We first screened latently infected PEL for TLR gene expres-
sion. BCBL-1 and BC-3 cells were harvested and expression of
TLRs 1 through 10 were analyzed by qPCR with specific TLR
primers. TLR profiling revealed that these cells express multiple
TLRs, including TLR7 and TLR8 (Fig. 1A).
To determine whether TLR activation could induce reactivation
of KSHV, we stimulated BCBL-1 and BC-3 cells with individual
cognate TLR ligands for 24 h, as well as a positive control, TPA
(Fig. 1B). Intracellular DNA viral load was determined by real-time
PCR and normalized for input using GAPDH copy number. Fold
activation for each sample was determined relative to the vehicle
control using the CT method. TLR2 stimulation with zymosan
or TLR4 stimulation with LPS derived from Escherichia coli strain
0111:B4 showed no significant difference in lytic gene expression.
Treatment of BCBL-1 cells with FSL-1 (TLR2/6 ligand) also had no
significant effect on replication compared with vehicle control and
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neither did TLR9 stimulation with CpG DNA. We observed a
decrease in viral DNA copy number in response to 1 g/mL
recombinant flagellin (TLR5 ligand) or 10 g/mL polyI:C (TLR3
ligand). This was in contrast to stimulation with single-stranded
RNA, a molecular pattern associated with viral infection that is
recognized by TLR7 and TLR8 (9). ssPoly-U is a synthetic homolog
of single-stranded RNA that specifically activates TLR8 (10).
Stimulation with 10 g/mL ssPoly-U resulted in a 4-fold increase in
viral genome copy number compared to control (Fig. 1B). More-
over, ssPoly-U reactivated KSHV to a greater extent than the
positive control, TPA. In summary, ssPoly-U was the only TLR
agonist that up-regulated KSHV lytic gene expression, suggesting
TLR8 activation reactivates KSHV from latency.
Since KSHV does not replicate to high titers in PEL, quantifi-
cation of DNA replication is not very sensitive. We therefore tested
TLR8-mediated reactivation of KSHV transcription in BCBL-1
cells. BCBL-1 cells were treated with ssPoly-U for various time-
points. ORF57 and ORF49 mRNA levels were subsequently ana-
lyzed by qPCR as a marker of viral reactivation. ssPoly-U treatment
resulted in 10-fold reactivation compared to the vehicle control.
In response to ssPoly-U, the levels of KSHV replication peaked at
48 h and declined after 72 h (Fig. 1C). For this experiment, we used
a combination of both TPA and sodium butyrate (NaB) as a more
potent positive control for KSHV reactivation, due to the variability
in responses of individual PEL lines to TPA alone. This combina-
tion gives considerably higher reactivation levels than either agent
alone. To establish that TLR8-mediated reactivation was common
to PEL in general, we screened additional PEL cells using ssPoly-U.
BCBL-1, BC-3, BCP-1, or VG-1 cells were treated with ssPoly-U for
48 h. This resulted in lytic reaction of KSHV in all samples (Fig. 1D).
This demonstrates that the activation of specific TLR signaling
pathways can lead to KSHV reactivation.
We next queried the specificity of TLR7 and TLR8 for mediating
KSHV lytic replication since both receptors recognize single-
stranded RNA. Both TLR7 and TLR8 reside within the endosome,
have similar structures, and are often functionally redundant (10,
11). We used several validated TLR7 and TLR8 ligands to test for
KSHV reactivation in BCBL-1 cells. CL-075 (3M-002) predomi-
nantly activates TLR8, and TLR7 to a lesser degree (10). Imi-
quimod has been shown to be specific for TLR7 (12). We stimulated
BCBL-1 cells with increasing concentrations of CL-075, Imi-
quimod, and CpG DNA (TLR9 ligand) and measured lytic gene
transcription. Increasing concentrations of CL-075 reactivated
KSHV approximately 2.5- and 4.5-fold over mock (Fig. 2A). Inter-
estingly, the TLR7 ligand, Imiquimod, reactivated KSHV to similar
levels as CL-075. In contrast, increasing concentrations of TLR9
Fig. 1. TLR stimulation and KSHV reactivation. (A) TLR expression in PEL cells.
Gene expression of the ten TLRs was determined in BCBL-1 and BC-3 by quanti-
tativeRT-PCRusingprimers specifictoeachhumanTLRgene.18Sgeneexpression
was used as a loading control. (B) KSHV reactivation in response to TLR agonists.
BCBL-1 cells were treated with 10 g/mL of the indicated TLR ligands and 20
ng/mL positive control (TPA) for 48 h. DNA was isolated and KSHV replication was
determined by qPCR for KSHV ORF49 or ORF57 gene expression compared to
vehicle control. (C) Time course of KSHV reactivation after TLR8 stimulation.
BCBL-1 cells were treated with vehicle control, ssPoly-U, or a combination of TPA
and Na-Butyrate. RNA was isolated at the indicated time points, and KSHV ORF49
and ORF57 gene expression was measured by qRT-PCR. (D) Single-stranded RNA
reactivates KSHV from 4 different PEL. BCBL-1, BC-3, BCP-1, and VG-1 PEL cell lines
were treated with vehicle control, 50 g/mL ssPoly-U, or a combination of TPA
and NaB for 48 h. Fold reactivation was calculated using real-time PCR values of
the TLR agonist treated samples versus the vehicle control treated samples. All
values were normalized to GAPDH.
Fig. 2. TLR7/8, and not TLR4, reactivates latent KSHV. (A) TLR7 and TLR8 ligands
reactivate KSHV. BCBL-1 cells were treated with increasing concentrations of
CL-075, Imiquimod, CpG DNA, or a combination of TPA and NaB for 48 h. (B) LPS
does not activate KSHV replication. BCBL-1, VG-1, BCP-1, and BC-3 cells were
treated with either LPS for 48 h or a combination of TPA and NaB. ORF57
transcription was measured by qRT-PCR using GAPDH as an endogenous control.
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agonist (CpG DNA) had no effect. In summary, stimulation of
TLR7 and TLR8 led to reactivation of latent KSHV. We used the
TLR4 agonist, LPS, as an additional negative control. We treated
BCBL-1, BC-3, BCP-1 and VG-1 PEL cells with 10 and 50 g/mL
LPS derived from E. coli strain 0111:B4. Increasing concentrations
of LPS did not result in KSHV reactivation from latency (Fig. 2B),
whereas the positive control (TPA and NaB) did reactivate the
virus. Another TLR4 agonist, LPS from E. coli strain K12, also
failed to induce KSHV lytic replication.
TLRs 7 and 8 are known to signal through the NF-B and IRF7
pathways, leading to the up-regulation of pro-inflammatory cyto-
kines and type I IFN, respectively. First, we looked at NF-B
activation following ssPoly-U stimulation by probing for IB-, an
inhibitor of NF-B nuclear translocation and transactivation. Upon
activation of TLR7/8, IB- is ubiquitinated and targeted for
proteasome-mediated degradation. Treatment of BCBL-1 cells
with ssPoly-U for 5 h induced IB- degradation (Fig. 3A),
indicating that the canonical NF-B pathway was activated by
TLR7/8 stimulation in PEL. Next, we tested whether the NF-B
promoter was activated in response to ssPoly-U stimulation.
BCBL-1 cells were nucleofected with 200 ng NF-B-luciferase
plasmid. Cells were pooled after 48 h, and either treated with
ssPoly-U or vehicle control. Sixteen hours post-treatment, cells
were harvested and analyzed for luciferase activity. ssPoly-U treat-
ment induced an approximate 7-fold activation of the NF-B
reporter compared to vehicle treated cells (Fig. 3B). Therefore,
ssPoly-U potently activates NF-B in BCBL-1 cells. ssPoly-U
stimulation also induced the up-regulation of IFN-, IFN- and
IFN-, as well as NF-B transcription in PEL (Fig. 3C). Induction
of NF-B and IFN-, , and  transcription serve as validated
markers for the activation of TLR signaling in many different cell
types (4). Moreover, activation of IFN-/ induces IRFs (including
IRF-7) in a positive-feedback loop necessary for amplification of
the initial innate immune response. Therefore, we analyzed IRF-7
protein expression 24 h after ssPoly-U stimulation of BCBL-1 cells
and observed IRF-7 up-regulation as expected (Fig. 3D). To
determine whether IRF-7 was critical for TLR7/8 induced lytic
replication, we transfected an IRF-7 dominant-negative (IRF-
7DN) construct (13) into BCBL-1 cells (Fig. 3E, Left). Forty-eight
hours later, the cells were split into 3 samples and treated with
equivalent amounts of either ssPoly-U, vehicle, or TPA. Twenty-
four hours post-treatment, cells were harvested and lysates were
analyzed for vIL-6 as a marker for lytic replication by western blot.
We found that IRF-7DN expression resulted in a marked reduction
of KSHV lytic reactivation compared to vector control (Fig. 3E,
Right). Taken together, our data demonstrate that the TLR7/8
pathway is activated in response to ssPoly-U stimulation of PEL and
imply that activation of this pathway can lead to KSHV reactivation
from latency in B lymphocytes. IRF-7 is a critical component of this
signaling pathway, whose activation by TLR7/8 is required for viral
reactivation.
RTA/ORF50 is the key lytic switch protein of KSHV. It is
necessary and sufficient to activate KSHV replication (14). We
therefore queried whether TLR7/8 signaling in PEL activated
the KSHV RTA/ORF50 promoter. BCBL-1 cells were nucleo-
fected with 5 g ORF50 promoter-luciferase reporter plasmid,
and 48 h post-transfection, cells were pooled and treated with
ssPoly-U RNA or vehicle. After 16 h, luciferase activity was
quantified as previously described (7). ssPoly-U treatment re-
sulted in a 7-fold increase in luciferase activity compared with
vehicle control (Fig. 4A). Hence, ssPoly-U-induced TLR7/8
signaling can activate the RTA promoter.
Next, we measured KSHV viral DNA in the ssPoly-U treated
BCBL-1 cells (Fig. 4B), and were able to detect a 4-fold increase in
viral DNA levels. To corroborate these results, KSHV early lytic
protein (ORF59) expression was analyzed by immunofluoresence
assays (IFA). KSHV ORF59 was detected in ssPoly-U treated
BCBL-1 cells as well as the positive control, but not in mock-treated
cells (Fig. S1). Similar results were obtained when we analyzed the
expression of KSHV vIL-6 in ssPoly-U-treated cells by western blot
analysis (Fig. 4C). In summary, our data demonstrate that ssPoly-U
stimulates the KSHV RTA promoter and induces KSHV early lytic
gene transcription, replication, and the expression of early lytic
proteins, vIL-6 and ORF59.
Although the above data suggested that KSHV lytic gene tran-
scription and protein expression was activated by ssPoly-U treat-
ment of PEL, it remained possible that lytic replication was
incomplete. Therefore, we profiled genome-wide KSHV transcrip-
tion using our KSHV qPCR array (15, 16). We treated BCBL-1 and
BC-3 cells with either ssPoly-U or TPA (positive control) for 48 h
and analyzed KSHV transcription. Two independent cell lines,
BCBL-1 and BC-3, showed up-regulation of KSHV viral gene
expression 48 h after ssPoly-U treatment (Fig. 5A). Their expression
profile resembled that of the positive control, TPA. As a negative
control, we treated BCBL-1 and BC-3 cells with 50 g/mL LPS for
48 h, but did not observe any KSHV reactivation (Fig. 5A). LPS
treated BCBL-1 cells displayed the same transcription profile as the
vehicle control-treated cells.
We also performed a time course experiment. BCBL-1 and
BC-3 cells treated for 0 h, 48 h, and 72 h with ssPoly-U or TPA
displayed lytic replication at the 48 h and 72 h time points, with
peak activation at 48 h (Fig. 5B). These results indicate that
Fig. 3. Single-stranded RNA activates an innate immune response. (A) Single-
stranded RNA activates the canonical NF-B pathway. IkB- protein expression
was determined by western blot 5 h post-treatment with ssPoly-U. (B) Single-
stranded RNA activates the NF-B promoter in PEL. BCBL-1 cells were nucleo-
fected with 200 ng NF-B promoter-luciferase plasmid. After 48 h, cells were
pooled and treated with ssPoly-U for an additional 16 h. Cells were then har-
vested and luciferase assays were performed. (C) TLR7/8 stimulation activates IFN
and NF-B transcription. BC-3 and BCBL-1 cells were treated with 50 g/mL
ssPoly-U for 48 h. IFN-,,, NF-kB1, and NF-kB2 transcription levels were deter-
mined by qRT-PCR. All values were normalized to GAPDH as the endogenous
control. (D) IRF-7 expression is up-regulated by single-stranded RNA. Cells were
treated with ssPoly-U for 24 h, lysed, and IRF-7 protein expression was analyzed
by western blot. (E) Inhibition of IRF-7 function blocks ssPoly-U-induced KSHV
reactivation. Flag-tagged IRF-7DN was analyzed by western blot 48 h after
nucleofection of BCBL-1 cells (Left). pcDNA3-IRF-7DN or pcDNA3 control trans-
fected cells were treated with 50 g/mL ssPoly-U, equivalent amount of vehicle
(mock sample), or 20 ng/mL TPA. Cells were analyzed for viral reactivation 24 h
post-treatment by performing a western blot for vIL-6 protein expression (Right).









complete KSHV lytic gene transcription occurs in response to
TLR7/8 stimulation of PEL.
To further verify that infectious virus was produced by ss-
Poly-U mediated reactivation of PEL, we treated BCBL-1 and
BC-3 cells for 48 h with 50 g/mL ssPoly-U. Supernatants were
subsequently harvested and used to infect uninfected Vero cells.
Ninety-six hours postinfection, viral DNA was isolated and
KSHV viral loads were analyzed using qPCR with ORF57
primers. As shown in Fig. 5C, treatment of BCBL-1 and BC-3
cells resulted in approximate 5- and 20-fold increases in pro-
duction of infectious KSHV virions, respectively. Of note, the
endogenous levels of TLR8 in these 2 cell lines may correlate
with differences in lytic replication between PEL cells. BCBL-1
cells have reduced levels of TLR8 expression compared to BC-3
(Fig. 1A), which may explain observed differences in infectious
virus produced upon ssPoly-U stimulation of different PEL.
To demonstrate that TLR7/8 stimulation was necessary for
ssPoly-U induced KSHV lytic replication, we used TLR7- and
TLR8-specific shRNA vectors to create stable BCBL-1 cells con-
taining knock-down of either TLR7 or TLR8. shRNA directed
against luciferase was used as a control. We achieved moderate
knock-down of TLR7 and complete loss of TLR8 in our knock-
down stable cells (Fig. 6A).
BCBL-1 cells knocked-down for TLR7 or for TLR8 were used in
ssPoly-U reactivation assays. Viral reactivation was measured by
western blot analysis for the lytic protein, vIL-6. The control cell
line, psiLuciferase-BCBL-1, showed considerable reactivation after
treatment with ssPoly-U (Fig. 6B). Treatment of psiTLR7-BCBL-1
with ssPoly-U resulted in slightly reduced vIL-6 expression, com-
pared to the psiLuciferase-BCBL-1 treated cells, demonstrating a
potential role for TLR7 in KSHV reactivation. However, ssPoly-U
treatment of the psiTLR8-BCBL-1 cells displayed substantially
reduced vIL-6 expression compared to the psiLuciferase-BCBL-1
treated cells. Importantly, all of the knock-down cell lines remained
similarly responsive to lytic reactivation by TPA, and showed
considerable reactivation (Fig. 6B). In summary, while TLR7 may
play a role in KSHV reactivation, TLR8 activation is more impor-
tant for viral reactivation since the TLR8 knock-down cells showed
a significant reduction in ssPoly-U-stimulated viral reactivation.
To translate our results to a physiologically relevant setting, we
used the single-stranded RNA virus, vesicular stomatitis virus
(VSV), for infection of PEL. VSV is endocytosed in a clathrin-
dependent manner (17, 18) and is known to activate TLR7/8 in
mouse and human cells (19). BCBL-1 cells were infected with VSV
at an MOI of 1, or treated with TPA as a positive control. KSHV
vIL-6 protein expression was determined 24 h and 48 h postinfec-
tion. Infection with VSV resulted in KSHV reactivation at both time
points (Fig. 6C). Similar results were seen with VSV infection at 0.1
MOI. VSV-induced reactivation was also accompanied by in-
creased NF-B, IFN-, , and  transcription (Fig. S2) and cell
death was visually observed. Thus, single-stranded RNA, specifi-
cally viral RNA, is capable of inducing KSHV reactivation.
Discussion
In summary, we report evidence for KSHV reactivation through
TLR signaling. TLR7/8 mediated reactivation from latency offers
a paradigm for how KSHV may initiate lytic replication in vivo.
Periodic reactivation of herpesviruses is important for the estab-
lishment of new latent reservoirs of virus, viral transmission, and
persistence in the host. Since human herpesviruses establish life-
long latency in their hosts, it is very plausible that a latently infected
cell is exposed to infection by a secondary pathogen, be it a virus,
bacterium, or fungus. We report that secondary viral infection that
is dependent on endosomal entry and stimulation of TLR7/8
signaling can lead to reactivation of latent KSHV from B lympho-
cytes. It is well-established that VSV activates TLR7/8. Although
VSV is a rhabdovirus and a natural pathogen of livestock, human
infections have been documented (20, 21), and VSV can infect
human B lymphocytes (22). Other RNA viruses that activate
TLR7/8, such as dengue virus, also infect B lymphocytes (23). Of
note, it was previously reported that infection of PEL with VSV-
pseudotyped HIV particles reactivated KSHV (24), although the
exact mechanism was not deduced. Since HIV RNA is known to
activate TLR7 and TLR8 (9, 25), the observed outcome in this
earlier study may be attributable to HIV RNA-induced activation
of TLR7/8 in PEL.
In immunosuppressed KSHV-positive individuals, KSHV reac-
tivation rates may be increased by secondary infections that trigger
TLR7/8 activation. Since lytic replication of KSHV is linked to an
increased risk of KSHV-associated cancers (26), one can speculate
that KSHV-positive individuals exposed to TLR7/8-activating
pathogens are at a higher risk for developing KSHV-associated
malignancies. Endogenous RNAs from necrotic cells also activates
TLR7/8 (27). Hence, it is equally plausible that KSHV reactivation
is triggered by endosomal trafficking of endogenous RNA from
necrotic cells. A recent publication indicates that MHV-68 can also
be reactivated in vivo by TLR signaling (28), although it was shown
Fig. 4. Single-stranded polyU RNA activates KSHV replication. (A) ssPoly-U
activates the KSHV RTA/ORF50 promoter. BCBL-1 cells were nucleofected with 5
g RTAp-Luciferase reporter plasmid and 48 h later cells were stimulated with
ssPoly-U or vehicle control for 16 h. Luciferase activity of both samples was
measured. (B) KSHV viral load analysis. KSHV viral DNA was isolated 48 h after
treatment of BCBL-1 cells with ssPoly-U or vehicle control. QPCR was performed
with vIL-6 primers to determine viral DNA loads. (C) Viral Reactivation. Western
blotforKSHVvIL-6andactin(loadingcontrol)aftertreatmentofBCBL-1cellswith
the indicated agonists.
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that multiple TLR ligands could reactivate MHV-68 from B
lymphocytes. This may reflect a biological difference between the
two viruses, or the difference in TLR signaling between normal and
malignant B lymphocytes.
Lastly, our data have implications for oncolytic therapy of viral
cancers. There is a growing interest in using VSV oncolysis to treat
tumors (29, 30). Our data suggests that VSV infection of KSHV-
infected lymphomas results in oncolysis, but also reactivates KSHV.
This may be detrimental to KSHV-positive cancer patients since
VSV oncolysis would inadvertently aid viral reactivation and dis-
semination. Thus, for some viral cancers it may be advisable to use
VSV oncolytic treatment in combination with viral replication
inhibitors, such as ganciclovir, to prevent reactivation and spread of
the virus to naïve cells in the host.
Defining the physiological stimuli of reactivation from latency
is a fundamental question in herpesvirus biology. We report
evidence of innate immune receptors mediating KSHV reacti-
vation. Moreover, TLR7/8 signaling mediated by secondary
infection of KSHV-infected B lymphocytes not only induces
KSHV reactivation and lytic replication, but also allows the virus
to propagate itself and escape a cell that is fated to die. This
Fig. 5. Whole genome profiling of KSHV after ssPoly-U treatment. (A) ssPoly-U
induces KSHV replication. KSHV viral arrays were performed after treatment of
BCBL-1 and BC-3 with 50 g/mL LPS, 50 g/mL ssPoly-U, or a combination of TPA
and NaB. Heat maps for each array are shown. (B) Time course of KSHV replica-
tion. Heat map of KSHV viral arrays after 0 h, 48 h, and 72 h treatment with 50
g/mL ssPoly-U. Relative gene expression levels are represented by blue, white,
and red, which indicate no detectable, intermediate, or high KSHV gene expres-
sion, respectively. (C) ssPoly-U reactivation of PEL generates infectious KSHV
virions. BCBL-1 and BC-3 cells were treated with 50 g/mL ssPoly-U, an equivalent
amount of vehicle, or 20 ng/mL TPA. Forty-eight hours post-treatment, superna-
tants were harvested and used to infect Vero cells. Ninety-six hours postinfection
of Vero cells, intracellular DNA was isolated and KSHV viral loads were quantified
by qPCR. Values were normalized to GAPDH. Fold increase in KSHV viral loads
from ssPoly-U treated PEL, compared to mock-treated PEL is shown.
Fig. 6. TLR7/8 stimulation mediates KSHV reactivation in response to single-
stranded RNA and VSV infection. (A) Knock-down of TLRs 7 and 8 in BCBL-1 cells.
Western blot for TLR7 and TLR8 protein expression in BCBL-1 cells stably trans-
fected with the psiRNA-luciferase control, psiRNA-TLR7, or psiRNA-TLR8 plas-
mids.Tubulin is shownasa loadingcontrol. (B)TLR7/8mediateKSHVreactivation.
ssPoly-U treatment of psiRNA-luciferase, psiRNA-TLR7, and psiRNA-TLR8 stable
BCBL-1 cell lines was performed. Expression of the lytic protein, vIL6, was deter-
mined by western blot 24 h after ssPoly-U treatment of each cell line. Tubulin is
shown as a loading control. (C) VSV infection of PEL mediates KSHV reactivation.
BCBL-1 cells were infected with VSV at an MOI of 1. KSHV vIL-6 protein expression
was determined by western blot analysis.









ensures KSHV survival and persistence for the lifetime of the
infected host.
Materials and Methods
Cell Culture. PEL cells were maintained in RPMI medium 1640 (Cellgro) containing
10% FBS, 1% penicillin-streptomycin (PS), and 0.05 M beta-mercaptoethanol.
Vero, HeLa, and BHK cells were maintained in DMEM media containing 10% FBS
and 1% PS. Cells were maintained at 37 °C in 5% carbon dioxide.
TLR Expression. Toll-like receptor screening of PEL cell lines was carried out by
isolating RNA, generating cDNA, and analyzing gene expression by quantitative
real-time PCR using TLR and 18S specific primers (SA Biosciences) according to the
manufacturer’s instructions. qPCR products were resolved on a 1% agarose gel.
TLR Stimulations. PEL cells (1  105/mL) were resuspended in 500 L of 2%
FBS/RPMI. TLR agonists (Invivogen) FSL-1 (TLR2/6), zymogen (TLR2), poly I:C
(TLR3), lipopolysaccharide (TLR4), recombinant flagellin (TLR5), imiquimod
(TLR7), gardiquimod (TLRs 7/8), CL-097 (TLR7), single-stranded poly U (TLR 8), and
CpG DNA (TLR9) were reconstituted in water according to the manufacturer’s
recommendations and TLR stimulations performed at the indicated concentra-
tions. For positive controls, 20 ng/mL TPA (Sigma) and 0.1 mM NaB (Sigma) in
DMSO was used. Cells were harvested and viral load assays were performed as
described below. Additionally, western blots, promoter reporter assays, and
immunofluorescence assays were also performed and are detailed in SI Materials
and Methods.
Viral Load Assay. For intracellularviral loadassays,DNAwas isolatedusingDNeasy
kit according to manufacturer’s instructions (Qiagen). For KSHV transcription,
cells were harvested and RNA isolated using RNeasy Plus RNA isolation kit
(Qiagen) followed by treatment with 1 unit RQ1 DNase (Promega). cDNA was
reverse transcribed from a minimum of 100 ng RNA using MMLV reverse tran-
scriptase (Invitrogen) and random hexamer primers (Invitrogen). Fold gene ex-
pression compared to mock treated samples was determined by quantitative PCR
(qPCR) using Sybr GREEN PCR master mix (Applied Biosystems). Primers used are
described in SI Materials and Methods. The qPCR reactions were run on an ABI
7000 or ABI 7300 machine (Applied Biosystems). Relative fold calculations were
determined by the CT method (15).
IRF-7 Dominant-Negative (IRF-7DN) Assays. BCBL-1 cells (1  106) were nucleo-
fected using 2 g Flag-tagged pcDNA3-IRF-7 dominant-negative plasmid (a kind
gift from Drs. Shunbin Ning and Joseph Pagano) or pcDNA3 vector control.
Forty-eight h postnucleofection, cells were split into 3 samples, and each sample
was stimulated with either ssPoly-U, vehicle, or TPA for 24 h. Expression of
IRF-7DN was verified by western blot with an anti-Flag antibody.
KSHV Viral Arrays. BCBL-1 cells were treated with TLR agonists for 48 h unless
otherwise noted. RNA was isolated and cDNA generated as described previously
(15). Real-time qPCR profiling of KSHV genes was performed followed by hier-
archical clustering using ArrayMinerTM software (Optimal Design) as previously
described (15).
KSHV Infection Assay. BCBL-1 or BC-3 cells were treated with ssPoly-U, vehicle, or
TPA as described for 48 h. Supernatants were harvested and added to confluent
monolayers of uninfected Vero cells in a 12-well dish. Polybrene (4 g/mL) was
added to each well and the plate was spinoculated at 2,500 rpm for 1.5 h at 30 °C
as previously described (7). Ninety-six hours postinfection, intracellular KSHV viral
loads were determined by real-time PCR.
Stable Knock-Down of TLR7 and TLR8 in BCBL-1 Cells. BCBL-1 cells (1  106) were
transfected by either nucleofection (Amaxa) or Hyperfect reagent (Qiagen) with
plasmids psiRNA-Luciferase, psiRNA-TLR7, or psiRNA-TLR8 (Invivogen). Cells were
selected in 100 g/mL Zeocin 48 h postnucleofection. BCBL-1 cells stably express-
ing the individual shRNAs were verified by GFP expression and TLR7/TLR8 protein
expression as described above.
Vesicular Stomatitis Virus Infections. Vesicular stomatitis virus (Orsay strain; a kind
gift from Dr. Doug Lyles) was grown on HeLa cells. BCBL-1 (1  105) were infected
with 0.1 and 1.0 MOI for 24 and 48 h in 2% RPMI, in a 48-well dish at 37 °C. Cell
lysates were subjected to western blot analysis for vIL-6 expression as described
above.
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